APP modulates KCC2 expression and function in hippocampal GABAergic inhibition

Ming Chen¹, Jinzhao Wang¹, Jinxiang Jiang²,³, Xingzhi Zheng¹, Nicholas J Justice⁴, Kun Wang¹, Xiangqian Ran¹, Yi Li¹, Qingwei Huo¹, Jiajia Zhang¹, Hongmei Li⁵, Nannan Lu¹, Ying Wang¹, Hui Zheng⁵, Cheng Long¹,³, Li Yang²,³,⁶

¹School of Life Sciences, South China Normal University, Guangzhou, China; ²School of Psychology and Center for Studies of Psychological Application, South China Normal University, Guangzhou, China; ³Brain Science Institute, South China Normal University, Guangzhou, China; ⁴Institute of Molecular Medicine, University of Texas Health Sciences Center, Houston, United States; ⁵Huffington Center on Aging, Baylor College of Medicine, Houston, United States; ⁶Guangdong Key Laboratory of Mental Health and Cognitive Science, South China Normal University, Guangzhou, China

Abstract

Amyloid precursor protein (APP) is enriched at the synapse, but its synaptic function is still poorly understood. We previously showed that GABAergic short-term plasticity is impaired in App knock-out (App⁻/⁻) animals, but the precise mechanism by which APP regulates GABAergic synaptic transmission has remained elusive. Using electrophysiological, biochemical, molecular biological, and pharmacological analysis, here we show that APP can physically interact with KCC2, a neuron-specific K⁺-Cl⁻ cotransporter that is essential for Cl⁻ homeostasis and fast GABAergic inhibition. APP deficiency results in significant reductions in both total and membrane KCC2 levels, leading to a depolarizing shift in the GABA reversal potential (E_GABA). Simultaneous measurement of presynaptic action potentials and inhibitory postsynaptic currents (IPSCs) in hippocampal neurons reveals impaired unitary IPSC amplitudes attributable to a reduction in a₁ subunit levels of GABA_A R. Importantly, restoration of normal KCC2 expression and function in App⁻/⁻ mice rescues E_GABA, GABA_A R a₁ levels and GABA_A R mediated phasic inhibition. We show that APP functions to limit tyrosine-phosphorylation and ubiquitination and thus subsequent degradation of KCC2, providing a mechanism by which APP influences KCC2 abundance. Together, these experiments elucidate a novel molecular pathway in which APP regulates, via protein-protein interaction with KCC2, GABA_A R mediated inhibition in the hippocampus.

DOI: 10.7554/eLife.20142.001

Introduction

APP is a type I single pass transmembrane protein highly expressed in the central nervous system (CNS) which is processed by α-, β-, and γ-secretases (Hardy and Selkoe, 2002) to generate beta amyloid (Aβ) peptide fragments that comprise the amyloid plaques found in Alzheimer’s disease (AD) patients post-mortem. The deleterious impact of Aβ has been studied extensively, with the recent discovery of the potent toxicity of Aβ oligomers on neuronal and synaptic activities (Hsieh et al., 2006; Kim et al., 2006; Wei et al., 2010). Despite advances in our understanding of how Aβ generation drives AD progression, the physiologic role of APP has proven more difficult to elucidate (De Strooper and Annaert, 2000). APP has been detected in vesicular fractions of...
eLife digest Alzheimer’s disease is the most common form of dementia. One of the hallmarks of the disease is the formation of sticky protein clumps called amyloid plaques in the brain. These plaques are formed from specific fragments of a protein called APP. The intact form of APP is essential for synapses (the junctions across which neurons transmit signals) to form and work correctly.

The hippocampus is one of the first brain regions to be affected in Alzheimer’s disease and is important for forming memories and emotions. In the hippocampus, GABA<sub>A</sub> receptors at synapses normally tightly regulate synaptic signaling by reducing the ability of the receiving neuron to respond, but this inhibition is disrupted in Alzheimer’s disease. Studies suggest that APP can affect how GABA<sub>A</sub> receptors transmit signals, but it is not known how it does so. One possibility is that APP regulates a protein called KCC2 that helps to maintain the inhibitory effect of GABA<sub>A</sub> receptors.

To investigate this, Chen et al. genetically modified mice to lack the gene that produces APP. These mice had a lower level of KCC2 in their hippocampus than normal mice, and their GABA<sub>A</sub> receptors were less able to inhibit synaptic signaling. Further experiments demonstrated that APP physically interacts with KCC2 and maintains normal levels of the protein by preventing it from being chemically modified and degraded.

Chen et al. also showed that treating mice that lack APP with specific compounds can restore KCC2 activity and return the behavior of synaptic GABA<sub>A</sub> receptors to normal. Future studies in mice (and eventually people) that exhibit symptoms of Alzheimer’s disease will help to determine whether KCC2 is important in the development of the disease. If so, modifying the levels of the KCC2 protein in the brain could potentially help to slow down memory loss in Alzheimer’s disease. DOI: 10.7554/eLife.20142.002
degradation of KCC2. However, which signaling pathways regulate these phosphorylation events and KCC2 degradation are largely unknown.

In the current study, we aimed to elucidate the synaptic mechanisms underlying APP regulation of hippocampal GABAergic inhibition. We show that APP mediates GABAergic inhibition via a direct protein-protein interaction with KCC2, which stabilizes KCC2 on the cell membrane. APP deficiency causes a loss of acting force holding KCC2 on site, resulting in increased KCC2 degradation via both tyrosine-phosphorylation and ubiquitination, decreased KCC2 levels and, sequentially, a depolarizing shift of $E_{\text{GABA}}$ and impairment in GABA$_A$R activities.

**Results**

**APP deficiency results in a depolarizing shift of $E_{\text{GABA}}$**

In order to test the idea that loss of APP changes the cellular ionic balance of Cl$^-$, thereby altering GABAergic transmission, we used gramicidin perforated patch clamp measurements in acute hippocampal brain slices (Figure 1A) that allows maintenance of an intact intracellular chloride concentration to estimate the IV-relationship of GABAergic currents (Chavas and Marty, 2003). We observed a positive shift of $E_{\text{GABA}}$ in App$^{-/-}$ hippocampal CA1 compared to WT controls (WT, $-83 \pm 6$ mV; App$^{-/-}$, $-45 \pm 7$ mV).

---

**Figure 1.** GABA reversal potential shifts toward depolarization in hippocampus of App$^{-/-}$ mice. (A) Slice preparations were made from the hippocampus and neurons were recorded in CA1 (inset). Pipettes were positioned to clamp neurons (Rec) while puffing molecules onto the cell (Puff). Scale bar: 10 µm. (B) Sample traces showing perforated patch recording of $E_{\text{GABA}}$ in WT and App$^{-/-}$ hippocampal slices. Currents were recorded at the indicated holding potentials shown to the left of each trace. (C) Graph shows I–V plots for the traces shown in B. (D) Quantification of $E_{\text{GABA}}$ shows a significant depolarizing shift in App$^{-/-}$ mice compared to WT controls (WT, $n = 16$ cells from five mice; App$^{-/-}$, $n = 20$ cells from five mice). *p<0.05; Student’s t-test.

DOI: 10.7554/eLife.20142.003

The following figure supplement is available for figure 1:

**Figure supplement 1.** GABA reversal potential shifts toward depolarization in App$^{-/-}$ hippocampal cultures.

DOI: 10.7554/eLife.20142.004
App−/−, −64 ± 5 mV; p=0.02 (Figure 1B–D), accompanying with identical resting membrane potentials (WT, −61 ± 1.4 mV; App−/−, −59 ± 1.5 mV; p=0.2). We repeated perforated patch recordings in hippocampal cultures and observed a similar depolarizing shift of E_GABA in App−/− neuronal cultures (WT, −82.5 ± 4 mV; App−/−, −67 ± 3.8 mV; p=0.02) (Figure 1—figure supplement 1).

**uIPSC amplitude and GABA_A R α1 subunit levels are reduced in App−/− hippocampus**

Loss of APP impairs GABAergic synaptic transmission (Seabrook et al., 1999; Yang et al., 2009). Given that we see a change in E_GABA in hippocampal neurons, we next asked whether loss of APP alters hippocampal IPSCs and GABA_A R expression. To do so, we performed dual whole-cell recordings in primary hippocampal cultures. We simultaneously evaluated electrically evoked presynaptic action potentials of a GABAergic interneuron labeled with GAD67+/-GFP, while patching a neighboring glutamatergic neuron and recording post-synaptic unitary IPSCs (uIPSCs) at a holding potential of −60 mV (Figure 2A). The mean uIPSC amplitude, evoked by a single presynaptic action potential in the GABAergic neuron, was significantly reduced in App−/− hippocampal cultures compared to WT control cultures (WT, 178 ± 42 pA; App−/−, 80 ± 19 pA; p=0.03) (Figure 2B–C). Similarly, puffing the GABA_A R agonist isoguvacine significantly reduced the amplitude of inhibitory currents in App−/− neurons compared to WT neurons (WT, 245 ± 26 pA; App−/−, 146 ± 24 pA; p=0.01) (Figure 2F–G). In contrast, the paired-pulse ratio (PPR) of uIPSCs in response to two consecutive action potentials in GABAergic neurons, at an inter-spike interval of 100 ms and 150 ms to assess synaptic release probability (Zucker and Regehr, 2002), was similar between WT and App−/− (Figure 2D–E) (100 ms; WT, 0.47 ± 0.04; App−/−, 0.56 ± 0.03; p=0.2; 150 ms; WT, 0.51 ± 0.06; App−/−, 0.55 ± 0.05; p=0.75). Consistent with impaired post-synaptic function accounting for these changes in APP mutants, we did not see a decrease in miniature IPSC (mIPSC) frequency, a measure of presynaptic efficacy (Fiszman et al., 2005; Goswami et al., 2012), when we compared App−/− and WT hippocampal slices (Frequency; WT, 2.9 ± 0.8 Hz; App−/−, 2.6 ± 0.7 Hz; p=0.8) (Figure 2—figure supplement 1C–D). Meanwhile mIPSC amplitude remained unchanged as well (Amplitude; WT, 14.8 ± 0.4 pA; App−/−, 13.9 ± 0.8 pA; p=0.7) (Figure 2—figure supplement 1C–D). In line with similar frequencies of mIPSCs in WT and App−/− hippocampus, we observed identical numbers of GABAergic neurons in the hippocampus of App−/− and WT mice (Figure 2—figure supplement 1A–B, Figure 2—source data 1). Finally, we looked at the abundance of GABA_A Rs in the hippocampus of APP mutant and WT animals. App−/− hippocampal lysates display reduced immunoreactivity of the α1 subunit, mediating fast inhibition, of the GABA_A R but not the other GABA_A R subunits, (Figure 2H–I, Figure 2—source data 1). Together, these data suggest that loss of APP may cause postsynaptic deficits in GABA_A R mediated GABAergic inhibition.

**APP deficiency leads to a reduction in total and plasma membrane KCC2 protein levels in hippocampus**

The electrical response of GABA_A Rs depends on the Cl⁻ equilibrium potential. The best characterized effectors of the Cl⁻ distribution in the CNS are KCC2 and the Na-K-2Cl cotransporter (NKCC1) (Ben-Ari, 2002; Kaila et al., 2014; Lee et al., 2011; Rivera et al., 1999). Since neuronal [Cl⁻] is mainly determined by the opposing activities of the Cl⁻ extruding transporter, KCC2, and the Cl⁻ importing NKCC1 (Blaesse et al., 2009), we compared hippocampal KCC2 and NKCC1 levels in WT and App−/− mice. We found that KCC2, but not NKCC1, protein levels were significantly reduced in App−/− hippocampus compared to WT littermate controls (Figure 3A–B, Figure 3—source data 1). KCC2 is mainly localized to the cell surface (Gauvain et al., 2011). To determine whether plasma membrane localization of KCC2 is decreased in APP mutants, we used surface biotinylation in hippocampal tissue (Figure 3A) or HEK293 cells transfected with KCC2 alone or KCC2 and hAPP695 (Figure 3C). We observed significantly reduced plasma membrane KCC2 levels in both App−/− hippocampus and HEK293 cells without co-transfection of hAPP695 (Figure 3B and D, Figure 3—source data 1). To examine KCC2 levels in intact tissue, we performed immunohistochemical staining in slice with anti-KCC2 antibody. We observed a selective loss of KCC2 immunoreactivity in App−/− mice in the CA1 region of the hippocampus (Figure 3E). To determine if this is due to altered transcription of KCC2 in APP mutants, we compared hippocampal KCC2 mRNA levels in App−/− and WT controls. KCC2 mRNA abundance was similar in App−/− and WT hippocampus (Figure 3F, Figure 3—
Figure 2. Decreased inhibitory IPSC amplitude and GABA<sub>\text{A}\text{R}\alpha1</sub> protein levels in App<sup>−/−</sup> mice. (A) Images of 12–14 DIV hippocampal cultures of Gad67<sup>+/+</sup> Gfp<sup>+</sup> mice. In the upper panel, under fluorescent illumination, GABAergic neurons appear green, and were stimulated (Sti) while recording from nearby glutamatergic cells (Rec) and puffing solutions (puff, lower panel DIC). Scale bar: 10 μm. (B) Sample traces showing postsynaptic uIPSC responding to presynaptic action potentials induced by short depolarizing voltage pulse injection (2 ms) to GABAergic neurons. (WT, black line; App<sup>−/−</sup>, red line). (C) Figure 2 continued on next page
Quantification of uIPSC amplitude shows a significant decrease in App−/− mice. (WT, n = 18 cells from five mice; App−/−, n = 17 cells from five mice). (D) Sample traces showing uIPSC recordings responding to injection of paired pulses to presynaptic GABAergic neurons (100 ms interpulse interval, left trace and 150 ms interpulse interval, right trace). (E) Quantification of paired pulse ratio (PPR) of uIPSCs with 100 ms and 150 ms interpulse intervals shows no significant difference between genotypes. (F) Sample traces showing evoked inhibitory currents responses to puffing 100 μM isoguvacine. (G) Quantification of isoguvacine-evoked inhibitory current amplitudes shows a significant decrease in App−/− mice. (WT, n = 14 cells from three mice; App−/−, n = 14 cells from three mice). (H) Representative immunoblots of hippocampal extracts from WT and App−/− littermates. (I) Quantification of the immunoblots reveals a significant decrease of GABAAR α1, but not other GABAAR subunits, levels in App−/− mice. Representative immunoblots of western blotting were from single experiment using three pairs hippocampal lysates, two repeats. *p<0.05; Student’s t-test.

The following source data and figure supplements are available for figure 2:

Source data 1. Contains source data for Figure 2 and all accompanying Figure 2—figure supplements 1, 2.
DOI: 10.7554/eLife.20142.005

Figure supplement 1. Similar numbers of GABAergic interneurons and mIPSC in WT and App−/− hippocampus.
DOI: 10.7554/eLife.20142.006

Figure supplement 2. Identical mEPSC and GluRs levels in between WT and App−/− hippocampus.
DOI: 10.7554/eLife.20142.007

source data 1). Together, these results indicate that APP is required to maintain normal KCC2 protein levels in the hippocampus via a post-transcriptional mechanism.

Full length APP stabilizes KCC2

To determine whether APP could stabilize KCC2 protein, we co-transfected HEK293 cells with KCC2 and hAPP695 cDNAs and assayed subsequent KCC2 protein levels. Cells co-transfected with both constructs displayed higher levels of KCC2 protein compared to cells transfected with only KCC2 (Figure 3G). APP is proteolytically processed into multiple extracellular and intracellular fragments. We tested these fragments individually to determine which fragment conferred KCC2 stability. We transfected HEK293 cells with KCC2+C99, KCC2+sAPPβ, or KCC2+hAPP695. Only full length APP but not the intracellular or extracellular fragments of APP prevented KCC2 degradation (Figure 3H, Figure 3—source data 1). Furthermore, using a sAPPβ knock in mouse model (sAPPβKI), we observed similarly reduced KCC2 levels in sAPPβKI hippocampus compared to WT mice (Figure 3I–J, Figure 3—source data 1). Together, our results indicate that full length APP is required to maintain normal levels of KCC2 protein.

APP and KCC2 physically interact to limit tyrosine phosphorylation and thus degradation of KCC2

To test whether APP regulates KCC2 through direct protein-protein interaction, we performed immunoprecipitation of KCC2 in HEK293 cells co-transfected with constructs encoding KCC2 and hAPP695. First, Coomassie blue staining was performed in transfected HEK293 cells showing a distribution of all proteins, including APP, pulled down by anti-KCC2 antibody (Figure 4—figure supplement 1). Next, APP was detected in anti-KCC2 immunoprecipitates (IP). Similarly, immunoprecipitation of APP co-precipitated KCC2 (Figure 4A). However, immunoprecipitation of the GABAAR α1 subunit co-transfected with hAPP695, we did not observe a direct physical interaction between APP and GABAAR α1 subunit (Figure 4B). Immunoprecipitation of KCC2 using hippocampal lysates co-precipitated APP as well (Figure 4C). Further, the APP-KCC2 interaction result was strengthened by proximity ligation assay (PLA) which would sensitively detect a very close surface interaction between proteins (Söderberg et al., 2006) (Figure 4D).

KCC2 is regulated post-translationally by tyrosine phosphorylation (Lee et al., 2010; Wake et al., 2007). Increased tyrosine phosphorylation of KCC2 enhances lysosomal degradation and thus decreases KCC2 levels (Lee et al., 2011, 2010). We hypothesized that APP may normally interact with KCC2 to prevent tyrosine phosphorylation and subsequent degradation. To test this hypothesis, we examined whether tyrosine phosphorylated KCC2 levels increased in the absence of APP. Hippocampal tissue from App−/− and WT mice was lysed and immunoprecipitated with anti-KCC2 antibody (Lee et al., 2010). Precipitates were blotted for tyrosine phosphorylated proteins using the anti-P-Tyr antibody, 4G10. We observed a robust increase in tyrosine phosphorylated KCC2 levels in APP
Figure 3. Full length APP is required for maintaining normal total and surface KCC2 protein levels. (A) Representative immunoblots of hippocampal extracts from WT and App<sup>−/−</sup> littermates. (B) Quantification of the immunoblots reveals a significant decrease in surface and total KCC2 protein levels in App<sup>−/−</sup> mice, while NKCC1 expression levels remain unchanged. Representative immunoblots of western blotting were from single experiment using three pairs of hippocampal lysates, three independent experiments (C) Representative immunoblots of HEK293 cells transfected with KCC2 and
KCC2 abundance and function can be rescued by CLPs

Next, we tested whether restoring KCC2 function in APP mutant mice would rescue changes in $E_{\text{GABA}}$ in hippocampal neurons. Chloride extrusion enhancers, CLP257 and CLP290, have been recently shown to restore $Cl^-$ extrusion capacity only in neurons with reduced KCC2 activity (Gagnon et al., 2013). We incubated hippocampal slices from APP mutant mice with CLP257 at 100 $\mu$M for 2 hr, and compared $E_{\text{GABA}}$ in slices treated with CLP257 or vehicle. Activation of KCC2 in App$^{-/-}$ hippocampus resulted in a hyperpolarizing shift of $E_{\text{GABA}}$ (CLP257, $-66 \pm 3$ mV; Control, $-54 \pm 2$ mV; $p=0.03$) (Figure 5A–B, Figure 5—source data 1). We next tested whether restoration of $Cl^-$ extrusion by chronic treatment with CLP290 (Gagnon et al., 2013) rescues KCC2 expression levels. CLP290 or vehicle was intraperitoneally injected once daily for seven consecutive days in App$^{-/-}$ mice, and hippocampal KCC2 levels were analyzed by western blotting. We observed a significant increase in KCC2 levels in CLP290 treated animals compared to vehicle treated App$^{-/-}$ mice (Figure 5C–D, Figure 5—source data 1).

It has been proposed that CLPs might increase KCC2 levels by reducing membrane KCC2 turnover (Gagnon et al., 2013). We then examined, in 293 cells transfected with KCC2, if treatment with CLP257 would indeed increase levels of membrane KCC2, and observed significantly enhanced surface KCC2 levels in CLP257 treated cells compared to vehicle control (Figure 5E–F, Figure 5—source data 1). These experiments could not distinguish whether CLP restored KCC2 levels by increasing insertion or decreasing removal of KCC2. Instead, the study suggested a rescue of KCC2 surface levels and function by CLPs in App$^{-/-}$ mice.

GABA$\alpha_1$ subunit abundance and GABA$\alpha_R$ mediated inhibition are dependent on KCC2

We observed decreases in GABA$\alpha_R$ $\alpha_1$ subunit protein levels and smaller evoked IPSC amplitudes in APP mutants (Figure 2). We then tested whether potentiating KCC2 function would rescue GABA$\alpha_R$ mediated inhibitory currents in APP mutant hippocampal slices. Evoked whole-cell inhibitory currents, induced by puffing the GABA$\alpha_R$ agonist isoguvacine, were recorded after incubation with CLP257 or vehicle for 2 hr, respectively. Evoked inhibitory current amplitudes were significantly
Figure 4. APP interacts with KCC2 to limit KCC2 tyrosine phosphorylation and degradation. (A) KCC2 interacts with APP in HEK293 cells by co-IP with both KCC2 and APP antibodies. Rabbit IgG (IP: IgG) was used as a negative control. (B) GABA_A Rα1 subunit does not co-immunoprecipitate with APP. (C) KCC2 interacts with APP by co-IP in hippocampal lysates. (D) KCC2 interacts with APP by proximity ligation assay (PLA). HEK293 cell was transfected with APP and KCC2, APP alone or KCC2 alone. Red: PLA signal indicates an existence of APP-KCC2 interaction; Blue: DAPI. Scale bar: 20 μm. (E) Hippocampal extracts from WT and App^-/- littermates were immunoprecipitated with an anti-KCC2 antibody (IP: KCC2) and probed with 4G10 antibody (anti-Phospho-tyrosine). Tyrosine phosphorylation of KCC2 is increased in App^-/- mice. Total KCC2 levels are also decreased in App^-/- mice. (Extracts were from three mice per genotype). (F) Representative immunoblots of KCC2 transfected HEK293 cells incubated with PP2 or vehicle. (G) Quantification of the immunoblots reveals a significant increase in KCC2 protein levels in PP2 treated HEK293 cells. Representative immunoblots of western blotting were from single experiment using three pairs of HEK293 lysates, two repeats. *p<0.05; Student’s t-test.

DOI: 10.7554/eLife.20142.011

The following source data and figure supplement are available for figure 4:

**Source data 1.** Contains source data for Figure 4.
DOI: 10.7554/eLife.20142.012

**Figure supplement 1.** Coomassie-stained SDS-PAGE gel showing KCC2 binding proteins after immunoprecipitated with an anti-KCC2 antibody (IP: KCC2).
DOI: 10.7554/eLife.20142.013
Figure 5. Restoring KCC2 expression and function in App<sup>−/−</sup> mice rescues hippocampal E<sub>GABA</sub>, GABA<sub>A</sub>R expression and IPSC amplitude. (A) Sample traces showing perforated patch recording of E<sub>GABA</sub> in CLP257 or vehicle treated App<sup>−/−</sup> hippocampal slices. Currents were recorded at the indicated holding potentials shown to the left of each trace. (B) Quantification of E<sub>GABA</sub> shows a significant hyperpolarizing shift in App<sup>−/−</sup> in CLP257 treated slices compared to vehicle controls (CLP257, n = 5 cells from three mice; Control, n = 5 cells from three mice). (C) Representative immunoblots of hippocampal extracts from App<sup>−/−</sup> treated with CLP290 or vehicle. (D) Quantification of the immunoblots reveals increased KCC2 protein levels in CLP290 treated App<sup>−/−</sup> mice. (E) Representative immunoblots of HEK293 cells transfected with KCC2 incubated with CLP257 or vehicle. (F) Figure 5 continued on next page
Quantification of the immunoblots reveals a significant increase in surface KCC2 protein levels when treated with CLP257, while total KCC2 levels remain unchanged, suggesting CLP257 might regulate KCC2 activity through blocking the latter’s turnover. (G) Sample traces of evoked inhibitory currents in response to puffs of 100 µM isoguvacine. (H) Quantification of isoguvacine-evoked inhibitory current amplitudes shows a significant increase in CLP257 treated App−/− hippocampus compared to vehicle controls (CLP257, n = 15 cells from three mice, Control, n = 15 cells from three mice), but no difference between CLP257 treated WT hippocampus and vehicle treated controls (CLP257, n = 9 cells from three mice, Control, n = 11 cells from three mice), suggesting that restoring KCC2 function rescues GABAAR mediated responses. (I) Representative immunoblots of hippocampal extracts from App−/− treated with CLP290 or vehicle. (J) Quantification of the immunoblots reveals increased GABAAR α1 protein levels in CLP290 treated App−/− mice. Representative immunoblots of western blotting were from single experiment using three pairs of HEK293 cells/ or hippocampal lysates of two independent experiments. *p<0.05; **p<0.01; ***p<0.001; Student’s t-test; quantified data of H, two-way ANOVA with post hoc tests.

DOI: 10.7554/eLife.20142.014

The following source data is available for figure 5:

Source data 1. Contains source data for Figure 5.

DOI: 10.7554/eLife.20142.015

larger in CLP257 treated App−/− slices compared to vehicle controls (App−/−: CLP257, 410 ± 34 pA; Vehicle, 278 ± 31 pA; p=0.008) (Figure 5G–H). Importantly, CLP257 treated WT slices did not differ significantly compared to vehicle controls (WT: CLP257, 612 ± 99 pA; Vehicle, 510 ± 109 pA; p=0.5) (Figure 5G–H). Additionally, chronic treatment with CLP290 rescued GABAAR α1 subunit protein levels as well (Figure 5I–J, Figure 5—source data 1). These results support a model in which APP loss of function results in reduced KCC2 levels and decreased KCC2 function, which causes the attenuation of GABAAR α1 expression and GABAAR mediated inhibitory current amplitudes, leading to a decrease of inhibitory tone in the hippocampus of APP mutants.

To test whether GABAAR α1 level changes are dependent on the presence of KCC2, we transfected HEK293 cells with GABAAR α1 or β2 subunits with and without co-transfection of KCC2. Interestingly, we only observed significantly reduced GABAAR α1, but not β2, subunit levels in the absence of KCC2 (Figure 6A–B, Figure 6—source data 1), suggesting a selective role of KCC2 on GABAAR α1 expression.

The mechanisms underlying the actions of KCC2 on GABAergic synapses are currently unclear (Chudotvorova et al., 2005). We next conducted experiments to elucidate how KCC2 regulates GABAAR α1 expression and thus GABAAR mediated inhibition. During immunoprecipitation of the GABAAR α1 subunit co-transfected with KCC2, we did not observe a direct physical interaction between KCC2 and GABAAR α1 subunit (Figure 6C), indicating that KCC2 regulation of GABAAR α1 expression was unlikely through a direct protein-protein interaction.

In a previous report the ubiquitin-like protein PLIC-1, which regulates the membrane trafficking of GABAAR, was shown to directly interact with GABAARs and promote their accumulation at the cell surface (Saliba et al., 2008). We next examined if KCC2 regulates GABAAR α1 levels through affecting PLIC-1 expression, however, Western blotting result showed identical PLIC-1 levels in hippocampus of WT and App−/− mice (Figure 6D–E, Figure 6—source data 1).

It has been shown that expression of GABAAR subunits is regulated by KCC2 expression through affecting intracellular Cl− gradient (Succcol et al., 2012). We thus proposed that KCC2-mediated Cl− extrusion might underlie KCC2 regulation of GABAAR α1 protein levels. If this was the case, treatment of WT hippocampus with a KCC2 inhibitor, VU02450551, would result in a reduction of α1 subunit of GABAAR protein levels as seen in App−/− hippocampus. Hippocampal GABAAR α1, several other GABAAR subunits and GluRs levels were analyzed by western blotting after incubation with VU02450551 or vehicle for 2 hr in WT hippocampus slices. We observed a significant decrease in GABAAR α1 levels, but not that of other GABAARs and GluRs subunits in VU02450551 treated WT hippocampus compared to vehicle control (Figure 6F and H, Figure 6—source data 1). Moreover, incubation of App−/− hippocampus with KCC2 inhibitor, VU02450551, further reduced levels of GABAAR α1 subunit but left GluR1 levels unchanged (Figure 6G and H, Figure 6—source data 1). These experiments suggested that blockade of Cl− extrusion by VU02450551 selectively affected levels of GABAAR α1, but not other GABAAR subunits tested in the present study.

It was well known that the expression of KCC2 and GABAergic inhibition parallel neuronal maturation and the emergence of low intracellular Cl− (Ben-Ari et al., 2012; Blaesee et al., 2009; Rivera et al., 1999). KCC2 exports Cl− and is weakly expressed at birth and upregulated as the brain...
Figure 6. GABA\(_{\alpha1}\) subunit is regulated by KCC2 expression through affecting intracellular Cl\(^-\). (A) Representative immunoblots of GABA\(_{\alpha1}\) + KCC2, GABA\(_{\alpha1}\) + pcDNA3, GABA\(_{\beta2}\) + KCC2, GABA\(_{\beta2}\) + pcDNA3, transfected HEK293 cells blotted with anti-GABA\(_{\alpha1}\) antibodies. (B) Quantification of the immunoblots reveals a significant increase in GABA\(_{\alpha1}\) levels in HEK293 cells co-transfected with GABA\(_{\alpha1}\) and KCC2, indicating KCC2 positively regulates expression of GABA\(_{\alpha1}\). (C) GABA\(_{\alpha1}\) does not co-immunoprecipitate with KCC2, suggesting that there was no protein-protein interaction between KCC2 and GABA\(_{\alpha1}\). (D) Representative immunoblots of hippocampal extracts from WT and App\(^{-/-}\) littermates. (E) Quantification of the immunoblots reveals identical PLIC-1 levels in between WT and App\(^{-/-}\) hippocampus. (F) Representative immunoblots of WT hippocampal slices incubated with a KCC2 inhibitor, VU02450551, or vehicle. (G) Representative immunoblots of App\(^{-/-}\) hippocampal slices incubated with a KCC2 inhibitor, VU02450551, or vehicle. (H) Quantification of the immunoblots reveals a significant decrease only in GABA\(_{\alpha1}\) levels of hippocampal tissue treated with VU02450551. (I) Representative immunoblots of hippocampal extracts from P7 and P35 WT mice. (J) Quantification of the immunoblots reveals significantly increased KCC2 and GABA\(_{\alpha1}\) levels in P35 compared to P7 WT mice.

Figure 6 continued on next page
matures (Plotkin et al., 1997; Rivera et al., 1999). To further evaluate the notion that rescue of GABA$_A$R $\alpha_1$ expression and GABA$_A$R mediated inhibition in App$^{-/-}$ hippocampus by restoring KCC2 levels involves alteration in intracellular Cl$^-$, we compared hippocampal KCC2 and GABA$_A$R $\alpha_1$ levels by western blotting in between postnatal day 7 (P7) (with high intracellular Cl$^-$ concentration) and P35 (with low intracellular Cl$^-$ concentration) WT mice, and observed significantly increased GABA$_A$R and KCC2 levels in P35 compared to P7 hippocampus (Figure 6I–J, Figure 6—source data 1). Similar to western blotting, immunofluorescent staining in P14 and P35 hippocampus displayed higher KCC2 levels in P35 compared to P14 mice (Figure 6—figure supplement 1). Data thus far suggested that rescue of GABA$_A$R $\alpha_1$ levels by restoring KCC2 in App$^{-/-}$ hippocampus involved, at least in part, an alteration of KCC2 mediated Cl$^-$ extrusion.

**APP also functions to suppress ubiquitination and thus degradation of KCC2**

Having shown that one way for APP to regulate KCC2 levels was to limit tyrosine phosphorylation and sequential degradation of KCC2, we speculated that blockade of tyrosine phosphorylation of KCC2 by mutating Y903A and Y1087A (mKCC2) which are two tyrosine phosphorylating sites of KCC2 may restore KCC2 levels in the absence of APP. However, mKCC2 levels were significantly lower without hAPP695 than with (Figure 7A–B, Figure 7—source data 1). Meanwhile, mKCC2 levels are identical in PP2 treated and non-treated HEK293 cells (Figure 7C–D, Figure 7—source data 1) confirming that mKCC2 did not undergo tyrosine phosphorylation, which met desired effect. Moreover, both IP and PLA examinations displayed direct protein-protein interaction between APP and mKCC2 (Figure 7E–F), suggesting that mutation of KCC2 at tyrosine phosphorylating sites did not disturb APP-KCC2 interaction. We then hypothesized that APP deficiency might cause a loss of acting force to hold mKCC2 on site leading to an increase in mKCC2 internalization, resulting in enhanced mKCC2 degradation via an unknown pathway rather than tyrosine phosphorylation. Interestingly, similar to co-transfection of mKCC2 with hAPP695 constructs, HEK293 cells co-transfected with mKCC2 and cylindromatosis (CYLD, a deubiquitinating enzyme) displayed higher levels of mKCC2 protein levels compared to cells transfected with only mKCC2 (Figure 7G–H, Figure 7—source data 1), implicating that mKCC2 might undergo ubiquitination and subsequent degradation in the absence of APP.

Next, treating mKCC2 transfected HEK293 cells (in the presence or absence of APP co-transfection) with the ubiquitination inhibitor MG132, we observed that MG132 increased levels of mKCC2 only in the absence (Figure 8A left–B, Figure 8—source data 1) but not in the presence (Figure 8A right–B, Figure 8—source data 1) of hAPP695, supporting that APP functions to limit mKCC2 ubiquitination. Moreover, using MG132 to block ubiquitination in HEK293 cells transfected with KCC2, we confirmed that ubiquitination occurred in KCC2 as well in the absence of APP (Figure 8C–D, Figure 8—source data 1).

We then examined whether KCC2 ubiquitination contributed to reduction of KCC2 levels in App$^{-/-}$ hippocampus. Hippocampal tissue from App$^{-/-}$ and WT mice was lysed and immunoprecipitated with anti-KCC2 antibody. Precipitates were blotted for ubiquitin/ubiquitinated proteins using the anti-ubiquitin antibody. We observed a robust increase in ubiquitinated KCC2 levels in App$^{-/-}$ hippocampus compared to littermate controls (Figure 8E–F). Furthermore, incubating hippocampus containing App$^{-/-}$ slices with MG132 significantly increased KCC2 levels (Figure 8G–H, Figure 8—source data 1). Moreover, surface KCC2 levels could also be increased by MG132 blockade of...
Figure 7. APP interacts with mKCC2 to limit mKCC2 ubiquitination and degradation. (A) Representative immunoblots of HEK293 cells transfected with mKCC2 and hAPP695. (B) KCC2 protein levels are elevated when HEK293 cells are transfected with both constructs. (C) Representative immunoblots of mKCC2 transfected HEK293 cells incubated with PP2 or vehicle. (D) Quantification of the immunoblots reveals identical KCC2 protein levels in between PP2 treated HEK293 cells and vehicle control. (E) mKCC2 interacts with APP. Rabbit IgG (IP: IgG) was used as a negative control. (F) PLA shows that mKCC2 interacts with APP. 

Chen et al. eLife 2017;6:e20142. DOI: 10.7554/eLife.20142
mKCC2 interacts with as well. HEK293 cell were transfected with both APP and mKCC2, APP alone, or mKCC2 alone. Red: PLA signal indicates an existence of APP-mKCC2 interaction; Blue: DAPI. Scale bar: 20 μm. (G) Representative immunoblots of transfected HEK293 cells. (H) Quantification of the immunoblots reveals a significantly increased KCC2 protein levels in HEK293 cell transfected with hAPP695 and CYLD, respectively. Representative immunoblots of western blotting were from single experiment using three pairs of lysates, two repeats. **p<0.01; ***p<0.001; Student’s t-test.

DOI: 10.7554/eLife.20142.020

The following source data is available for figure 7:
DOI: 10.7554/eLife.20142.019

Source data 1. Contains source data for Figure 7.
DOI: 10.7554/eLife.20142.020

KCC2 ubiquitination in HEK293 cells and App<sup>-/-</sup> hippocampus (Figure 8I–J, Figure 8—source data 1).

Data thus far indicated that KCC2 levels could be regulated post-translationally by ubiquitination as well as tyrosine phosphorylation in the absence of APP. APP-KCC2 interaction played a crucial role in suppressing KCC2 internalization and subsequent degradation via both tyrosine phosphorylation and ubiquitination. APP deficiency resulted in a loss of acting force to hold membrane KCC2, leading to enhanced KCC2 degradation in the hippocampus.

Restoring KCC2 by CLP257 did not rescue abnormal tonic GABAergic current in CA1 of App<sup>-/-</sup> mice

GABA has not only phasic but also tonic mode of action (tonic GABA current) and the latter involves extrasynaptic GABAA<sub>R</sub>s and/or reactive astrocytic GABA (Curia et al., 2009; Jo et al., 2014), and tonic GABA action has been implicated in AD mouse models (Jo et al., 2014; Wu et al., 2014; Yarishkin et al., 2015). We have previously shown that tonic GABA currents were impaired in the dentate gyrus (DG) of App<sup>-/-</sup> mice attributing to abnormal genesis and survival of DG newborn neurons (Wang et al., 2014b). We thus evaluated whether abnormal tonic GABA currents also occurred in APP deficient CA1 and, observed significantly reduced amplitude of tonic GABA current in the CA1 of App<sup>-/-</sup> mice compared to WT controls (WT, 19.1 ± 2.7 pA; App<sup>-/-</sup>, 9.1 ± 0.7 pA; p=0.002) (Figure 9—source data 1). Interestingly, restoring KCC2 by CLP257 incubation of App<sup>-/-</sup> hippocampal slice did not rescue impaired tonic GABA current (App<sup>-/-</sup>, 9.1 ± 0.7 pA; App<sup>-/-</sup>+CLP257, 11.9 ± 1.6 pA; p=0.1) (Figure 9—source data 1), suggesting that aberrant KCC2 levels and function might underlie impaired phasic but not tonic GABA current in the CA1 of App<sup>-/-</sup> mice.

Discussion

In this study, we demonstrate that APP regulation of KCC2 expression and function is required to maintain appropriate GABAergic signaling capacity in the hippocampus as summarized in Figure 10. This is supported by several lines of evidence: (1) APP deficiency results in a depolarizing shift of E<sub>GABA</sub> along with reduced amplitude of uIPSCs and tonic GABA current; (2) APP deficiency results in a significant reduction in the abundance of hippocampal KCC2, but not NKCC1, and GABAA<sub>R</sub> α1 subunit expression; (3) Phasic GABAergic signaling phenotypes can be rescued by CLPs enhancing KCC2 expression and function, suggesting that impaired regulation of KCC2 by APP is responsible for these fast inhibition deficits in APP mutants, while altered tonic GABA current might involve different mechanisms (Jo et al., 2014; Wu et al., 2014). Together, these data indicate that regulation of KCC2 by APP plays a critical role in the maintenance of normal hippocampal GABAergic inhibition. Identical mIPSC amplitude in between WT and App<sup>-/-</sup> hippocampus indicates that reduction in GABAA<sub>R</sub> α1 expression in App<sup>-/-</sup> does not impair basal inhibitory activity that requires activation of a portion of GABAA<sub>R</sub>, which is commonly observed when correlating altered receptors with miniature activities (Caraiscos et al., 2004; Chudotvorova et al., 2005).

In previous studies, we have shown that impaired GABAergic short-term plasticity evaluated by abnormal PPR of IPSCs is due, in part, to presynaptic alterations of L-type calcium channels (LTCCs) (Yang et al., 2009). However, we did not see changes in the PPR of uIPSCs in the present study. This may be due to the fact that IPSCs were induced by field stimulation in previous study, which activates multiple presynaptic GABAergic neurons, and corresponding LTCC currents. By contrast, in the present study, uIPSCs were evoked by a single presynaptic action potential in a single
Figure 8. APP deficiency causes an increase in KCC2 ubiquitination leading to a reduction of KCC2 levels. (A) Representative immunoblots of HEK293 cells transfected with mKCC2 alone, mKCC2 and hAPP695, incubated with MG132 or vehicle. (B) Quantification of the immunoblots reveals a significantly increased mKCC2 levels in HEK293 cell transfected with mKCC2 alone and incubated with MG132. (C) Representative immunoblots of HEK293 cells transfected with KCC2 alone (incubated with MG132); KCC2 and hAPP695. (D) Quantification of the immunoblots reveals a significantly increased KCC2 protein levels in KCC2 alone with MG132 incubation, which is similar to co-transfection of hAPP695 and KCC2, compared to KCC2 alone incubated with vehicle. (E) Representative immunoblots of supernatant before and after IP pull down of KCC2 in WT and App⁻/⁻ mice. (F) Hippocampal extracts from WT and App⁻/⁻ littermates immunoprecipitated with an anti-KCC2 antibody (IP: KCC2) and probed with ubiquitin antibody.

Figure 8 continued on next page
GABAergic neuron such that the involvement of presynaptic LTCCs is minimized. This system allowed us to focus on postsynaptic KCC2 dysfunction in APP mutant hippocampal neurons.

KCC2 is the principle mechanism used by neurons to lower internal $[\text{Cl}^-]$, which is required for adequate inhibitory synaptic transmission upon activation of GABA$_A$Rs and GlyRs (Braat and Kooy, 2015a; Kaila et al., 2014; Rivera et al., 1999). However, little is known about what regulates KCC2 expression and function. In an attempt to understand why KCC2 levels are diminished in APP mutants, we discovered a physical interaction between APP and KCC2. This interaction protects KCC2 from protein phosphorylation and ubiquitination which target the protein for degradation. These results suggest that APP is a novel protein binding-partner for KCC2. APP holds KCC2 on membrane through protein-protein interaction to maintain appropriate KCC2 levels, internal $[\text{Cl}^-]$ and GABA$_A$R mediated inhibition. Though increased activation of glutamatergic receptors has been shown to downregulate KCC2 expression and GABA$_A$R mediated current (Lee et al., 2011), neither amplitude, frequency of mEPSCs (Amplitude: WT, 13.3 ± 0.4 pA; App$^{+/-}$, 12.6 ± 0.8 pA; p=0.5; *p<0.05; **p<0.01; Student’s t-test.

Figure 8 continued

Ubiquitinated KCC2 is obviously increased in App$^{-/-}$ compared to WT mice (Each extract was from three mice per genotype, repeated twice). (G) Representative immunobots of App$^{-/-}$ hippocampus incubated with MG132 or vehicle. (H) Quantification of the immunobots reveals a significantly increased KCC2 protein levels in MG132 treated App$^{-/-}$ hippocampus implicating KCC2 underwent ubiquitination in the absence of APP. (I) Representative immunobots of surface KCC2 levels of HEK293 cells and App$^{-/-}$ hippocampus incubated with MG132 or vehicle. (J) Quantification of the immunobots reveals a significantly increased surface KCC2 levels in MG132 treated compared to vehicle control. Representative immunobots of western blotting were from single experiment using three pairs of HEK293 cells/ or hippocampal lysates, two repeats. *p<0.05; **p<0.001; Student’s t-test.

DOI: 10.7554/eLife.20142.021
The following source data is available for figure 8:
Source data 1. Contains source data for Figure 8.
DOI: 10.7554/eLife.20142.022

Figure 9. Reduced tonic GABA current in CA1 of App$^{-/-}$ hippocampus. (A) Sample traces of tonic GABA current in WT, App$^{-/-}$ and App$^{+/-}$ incubated with 100 μM CLP257. (B) Quantification of tonic GABA current amplitude shows a significant decrease in App$^{-/-}$ mice and CLP does not rescue tonic GABA current in App$^{-/-}$ hippocampus (WT, n = 10 cells from five mice; App$^{+/-}$, n = 10 cells from five mice; App$^{+/-}$+CLP257, n = 9 cells from five mice). *p<0.05; **p<0.01; one-way ANOVA.

DOI: 10.7554/eLife.20142.023
The following source data is available for figure 9:
Source data 1. Contains source data for Figure 9.
DOI: 10.7554/eLife.20142.024
Changes in KCC2 levels that occur in APP mutants can have wide ranging effects on the status of GABAergic signaling. Modulation of KCC2 protein levels has been reported to affect GABAA,R a1 and GABA mediated inhibition, which can be rescued by restoration of KCC2 expression and function.

Figure 10. A working model shows the mechanism underlying APP regulation of GABAA,R mediated inhibition. KCC2 transports Cl− outside the neuron maintaining low [Cl−]i in mature neurons and therefore insures an Cl− influx upon GABA binding to the GABAA,Rs. APP and KCC2 physically interacts to limit tyrosine phosphorylation, ubiquitination and sequential degradation of KCC2 to maintain abundant membrane KCC2 levels and hyperpolarizing EGABA in WT hippocampal neuron. APP deficiency leads to a loss of limit on tyrosine phosphorylation and ubiquitination of KCC2 and thus reduces KCC2 protein levels, resulting in depolarizing shift of EGABA, reduction of GABAA,R a1 and GABA mediated inhibition, which can be rescued by restoration of KCC2 expression and function.

DOI: 10.7554/eLife.20142.025

Chen et al. eLife 2017;6:e20142. DOI: 10.7554/eLife.20142

Frequency; WT, 0.2 ± 0.05 Hz; App−/− 0.4 ± 0.2 Hz; p=0.3) nor GluRs protein levels changed in hippocampus of APP mutants compared to WT controls (Figure 2—figure supplement 2A–D, Figure 2—source data 1). The results suggest that excitatory synaptic activity mediated by AMPA receptors may not be affected by loss of APP at the age tested.
postulated that altered KCC2 function in APP mutants accounts for changes in GABAergic signaling. To test this, we pharmacologically enhanced KCC2 function in App−/− mice and observed a rescue in both amplitudes of isoguvacine induced currents and GABA_A R α1 expression levels, indicating a rescue of GABAergic functional deficits by restoring KCC2 function. Moreover, we show that blockade of KCC2 mediated Cl− extrusion in WT hippocampus resulted in a reduction of GABA_A R α1 levels as seen in App−/− mice and, GABA_A R α1 levels are positively correlated with KCC2 expression and function during early stage of development. We thus reasoned that increase in KCC2 mediated Cl− extrusion might be responsible for upregulation of surface GABA_A R α1 levels.

Though the exact mechanism underlying how restoring KCC2 rescued surface GABA_A R α1 levels remains unclear, given that APP interacts directly with KCC2, and increasing KCC2 expression and function rescued GABAergic signaling phenotypes in App−/− hippocampus, we propose that KCC2 is the primary defect caused by APP deletion to alter GABAergic signaling, while changes in GABA_A R α1 levels and GABA_A R mediated inhibition are secondary to altered KCC2 expression and function.

Our results indicate that full length APP is required to maintain normal levels of KCC2 protein. Together with a recent study of the AppΔCT15-DM mice, a mouse model lacking the last 15 amino acids of APP as well as the APP homologue, APLP2, which demonstrated impairments of synaptic plasticity and hippocampal-dependent behavior (Klevanski et al., 2015), it is likely that APP proteolysis may be a mechanism for turning off normal APP functions which needs to be taken into account when exploring the pathophysiology of APP with respect to KCC2 regulation.

GABAergic signaling has been shown to be disrupted in many diseases of the nervous system (Braat and Kooy, 2015a), including fragile X syndrome and autism spectrum disorder (Braat and Kooy, 2015b; Han et al., 2014). Changes in KCC2 function may account for many GABAergic signaling deficits, as it has been shown to be involved in the pathogenesis of epilepsy, schizophrenia, autism and aging brain (Ben-Ari et al., 2012; Ferando et al., 2016; Tang et al., 2016; Tao et al., 2012). Though the GABAergic system appears to be resistant to Aβ toxicity (Selkoe, 2002), recent research has demonstrated dysfunctional GABAergic inhibition in AD (Verret et al., 2012). In the present study, we have described a cellular mechanism by which loss of APP function downregulates KCC2 to impair GABAergic signaling. Given the results presented here in APP mutant hippocampal neurons, if APP function is compromised in the context of progressing AD, this may lead to the gradual loss of GABAergic signaling capacity in the hippocampus and associated changes in memory function. Together with a most recent study revealing a critical role of KCC2 in information storage in aging brain (Ferando et al., 2016), the present study suggests that KCC2 might serve as a therapeutic target to improve GABAergic inhibition to potentially restore hippocampal function and improve memory in AD.

**Materials and methods**

**Animals and plasmids**

All experiments and animal housing were in accordance with procedures approved by the Ethics Committee for animal research at South China Normal University, according to the Guidelines for Animal Care established by the National Institute of Health. Both female and male mice were used in this study. App−/− and wild type (WT) mice (Zheng et al., 1995) were generated by crossing App+/− males and females obtained from Model Animal Research Center of Nanjing University (Nanjing, China). App−/− mice were crossed with Gad67+/+GFP mice (Tamamaki et al., 2003) (gift from Dr. Yuqiang Ding at Tongji University School of Medicine, Shanghai, China) when necessary to generate App−/−;Gad67+/+GFP and WT-Gad67+/+GFP controls. Soluble APP ectodomain beta (sAPPβ) knock in mice (Li et al., 2010), full length human APP (hAPP695), APP C-terminal fragments (C99) and sAPPβ constructs were from Hui Zheng lab at Baylor College of Medicine. The KCC2 construct was gift from John A Payne (School of Medicine, University of California). The GABA_A R α1 construct was gift from Gangyi Wu (South China Normal University, Guangzhou, China). CYLD construct was gift from Shaocong Sun (University of Texas MD Anderson Cancer Center, Texas, USA). GABA_A R β2 construct was from Yong Zhang (Peking University).
Neuronal culture
Cultured hippocampal neurons were prepared as described (Yang et al., 2009) with some modifications. Briefly, we dissected hippocampus from AppC/+/Gad67+/GFP and WT-Gad67+/GFP littersmates of P0/1 pups, trypsinized the tissue at 37°C for 30 min, and then gently triturated in culture medium containing 10% heat-inactivated fetal bovine serum using fire-polished pipettes, before centrifuging at 1000 rpm for 10 min. Cells were resuspended in Neurobasal Medium supplemented with B27 and L-glutamine (Invitrogen, Carlsbad, CA), and plated at 1–2 × 10⁴ cells/ml onto 13 mm poly-L-lysine coated coverslips. One day after plating, 4 M cytosine-D-arabinofuranoside (Ara-C) (Sigma) was added to prevent astrocyte proliferation. Cultures of 12–14 DIV were used for patch clamp recordings.

Electrophysiology
Whole-cell recording in acute hippocampal slices
Hippocampal slices (350 μm thick) were cut using a vibratome (LeicaVT1000S) in ice-cold cutting solution containing the following: 25 mM NaHCO₃, 2.5 mM KCl, 7 mM MgCl₂, 1.25 mM NaH₂PO₄, 7 mM Glucose, 0.5 mM CaCl₂, 115 mM Choline Cl. Slices were incubated for 45 min in artificial cerebrospinal fluid (aCSF) solution containing the following: 119 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl₂, 1.3 mM MgSO₄, 1 mM NaH₂PO₄, 11 mM D-glucose, 26.2 mM NaHCO₃. Pipettes were filled with an internal solution of 136.5 mM K-Gluconic acid, 17.5 mM KCl, 9 mM NaCl, 1 mM MgCl₂, 0.2 mM EGTA, 10 mM HEPES (pH 7.3) containing gramicidin A 10 μg/ml (Sigma; diluted from a stock solution of 10 mg/ml in DMSO). The recording aCSF contains: 140 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl₂, 1.2 mM MgCl₂, 11 mM D-glucose, 10 mM HEPES (pH 7.3). Both incubating and recording solutions were bubbled with 95% O₂ and 5% CO₂ throughout the experiment. We performed all the experiments for the determination of E_GABA values in the presence of TTX (1 μM), CNQX (20 μM), APV (50 μM) and Strychnine (1 μM) to block voltage-gated sodium channels, AMPA receptors, NMDA receptors, and GlyRs, respectively. A Picospritzer (Parker Instrumentation) was used to eject GABA (100 μM, 100 ms) directly onto neuronal soma through a fine pipette (~2 μm tip). For mEPSC and mIPSC recordings, the aCSF was supplemented with 1 μM TTX, and pipettes were filled with an internal solution of 100 mM Cs gluconate, 5 mM CsCl, 10 mM HEPES, 2 mM MgCl₂, 1 mM CaCl₂, 11 mM BAPTA, 4 mM ATP, 0.4 mM GTP. To record tonic GABA current, 10 μM CNQX and 50 μM APV were added into the aCSF to block glutamate receptors. The total tonic GABA current was revealed by the change of holding current after perfusion of 100 μM bicucullin (Bic). Pipettes were filled with an internal solution of 135 mM CsCl, 5 mM Na-phosphocreatine, 10 mM HEPES, 5 mM EGTA, 4 mM MgATP, 5 mM QX-314 and 0.5 mM Na₂GTP (pH 7.3) (Wu et al., 2014). Data were filtered during acquisition with a low pass filter set at 2 kHz using pClamp10 (Molecular Devices). Data analysis was performed offline with Clampfit 10.2 (Molecular Devices).

Whole-cell recording in hippocampal cultures
GABA reversal potential recordings were made using a perforated patch-clamp technique. Pipettes were filled with an internal solution of 140 mM KCl and 10 mM HEPES (pH 7.3) containing gramicidin A 50 μg/ml (Sigma; diluted from a stock solution of 50 mg/ml in DMSO). Data were filtered during acquisition with a low pass filter set at 2 kHz using pClamp10 (Molecular Devices). Data analysis was performed offline with Clampfit 10.2 (Molecular Devices).

Dual whole-cell patch-clamp recordings
The culture coverslips were transferred into a heated (30°C) submerged recording chamber, continuously perfused (2–3 ml/min) with tyrode buffer: 129 mM NaCl, 5 mM KCl, 0.01 mM Glycine, 1 mM MgCl₂, 2 mM CaCl₂, 25 mM HEPES, 30 mM D-Glucose. We performed all experiments for the determination of unitary inhibitory postsynaptic current (uIPSC), and paired-pulse ratio (PPR, uIPSC2/uIPSC1) values in the presence of CNQX (20 μM) and APV (50 μM) to block AMPA receptors and NMDA receptors, respectively. GABAergic neurons were patched in whole-cell, current-clamp configuration using an Axopatch 700B amplifier (Axon Instruments) Channel 1. The pipette solution contained 110 mM K-Gluconic acid, 10 mM NaCl, 1 mM MgCl₂, 10 mM EGTA, 40 mM HEPES, 2 mM ATP, 0.3 mM GTP (pH adjusted to 7.2 with NaOH). Pyramidal neurons were patched in voltage-clamp configuration and recorded at a holding potential of −60 mV using an Axopatch 700B.
amplifier (Axon Instruments) Channel 2. The pipette solution contained 100 mM Cesium Methanesulfonate, 10 mM NaCl, 10 mM TEA-Cl, 1 mM MgCl$_2$, 10 mM EGTA, 40 mM HEPES, 2 mM ATP, 0.3 mM GTP, 4 mM QX-314 (pH adjusted to 7.2 with NaOH). Before uIPSC recordings, voltage responses of presynaptic and postsynaptic cells were recorded by applying long hyperpolarizing and depolarizing current pulse (300 ms) injections to examine basic electrophysiological properties, including input resistance, single spike kinetics, voltage-current relationships, repetitive firing patterns, and firing frequency. For evoked GABA current recording, a Picospritzer (Parker Instrumentation) was used to eject isoguvacine (100 μM, 100 ms) directly onto neuronal soma through a fine pipette (~2 μm tip).

**Quantitative Real-time PCR (qRT-PCR)**

Mice brains were dissected and immediately frozen in liquid nitrogen. Total RNA was extracted using Trizol reagent. RNA pellets were resuspended in diethylpyrocarbonate-treated water and RNA concentration was measured using a Nanodrop2000c spectrometer (Thermo Scientific). RNA was DNase treated (DNase I, amplification grade, Invitrogen) and then reverse-transcribed using the Superscript III First-Strand Synthesis System (Invitrogen). Relative quantification of gene expression was performed using Taq Man probes and an ABI Prism 7000 Sequence Detection System. Platinum Quantitative PCR Super Mix-UDG w/ROX (Invitrogen) was used with the following primers and probes: App F-primer, (5’–3’) CCAAGAGGTCTACCCTGAACTGC; App R-primer, (5’–3’) AGGCAACGTTAGGAAATCAGC; Actβ F-primer (5’–3’) GTGACGTTGACATCCGTAAAGA; Actβ R-primer (5’–3’) TGAACAGTCCGCCTAGAAGCAC; Slc12a5 F-primer (5’–3’) GGGCAGAGAGTACGATGGC; Slc12a5 R-primer (5’–3’) TGGGGTAGGTTGGTGTAGTG. Assay efficiencies were experimentally determined using a five-point dilution series of cDNA spanning a 100-fold range in concentration. 0.025 μg cDNA template was used per reaction. Statistical analysis was performed on 2$^{-\Delta\Delta Ct}$ values.

**Immunohistochemistry**

Mice were anesthetized with intraperitoneal injection of 20% urethane (0.01 ml/g) and perfused transcardially with 0.9% physiological saline and 4% paraformaldehyde (PFA) in phosphate buffer (0.01 M PBS, pH 7.4). Following perfusion, the brains were dissected and post-fixed overnight in 4% PFA followed by a sucrose series (10%, 20% and 30%) solution at 4°C for cryoprotection. Serial coronal/sagittal sections of tissue were obtained using a freezing microtome. Free-floating sections were rinsed in PBS three times for 5 min and processed for antigen retrieval by boiling in 10 mM citrate buffer (pH 6.0) for 5 min. The sections were incubated in 3% H$_2$O$_2$ in PBS for 15 min at room temperature (RT) to quench endogenous peroxidases, washed three times for 5 min and subsequently incubated in 0.3% Triton X-100 in PBS for 2 hr. To block nonspecific binding, sections were incubated in 3% bovine serum albumin (BSA) for 30 min. Sections were then incubated overnight with primary antibody against KCC2 (Neuromab, 75–013; Millipore, 07–432) at 4°C. After three washes with PBS, secondary antibody (CWS) application was performed at RT for 2 hr followed by three additional washes with PBS for 10 min. The secondary antibody was visualized with 3,3-diaminobenzidine tetrahydrochloride (DAB, Sola). The reaction was terminated by rinsing in PBS and then sections were mounted on gelatin-subbed slides, dehydrated in ascending alcohol concentrations, cleared through xylenes, and covered with DPX resin. KCC2 immunofluorescent staining was conducted as described (Yang et al., 2009).

**Western blotting**

Mouse brains were homogenized using SDS lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA pH 8.0, 1% SDS) containing complete protease inhibitor cocktail (Roche). After 1 min of homogenization, the cellular debris was removed by centrifugation at 14000 rpm for 10 min at 4°C and supernatant was collected and denatured for 20 min at 75°C. Tissue lysates were subjected to SDS-PAGE (Bio-Rad) and transferred to nitrocellulose membranes. Membranes were blocked for 0.5 hr using 5% non-fat dry milk in TBS containing 0.5% Tween-20 (TBST), then incubated with specific primary antibodies against KCC2 (Neuromab, 75–013; Millipore, 07–432; Santa Cruz, sc-19419), NKCC1 (Abcam, ab191289), APP (Abcam, ab15272), 4G10 (Millipore, 16–452), PLIC-1 (ABGENT, AP2176c), GABA$_A$R subunits: α1 (Millipore, 06–868), α5 (Abcam, ab175195), β2 (Abcam, ab156000), δ (Abcam, ab110014), γ2 (Abcam, ab87328), GluR1 subunit (Abcam, ab31232) and GluR2 subunit...
(Abcam, ab206293) of AMPA receptors, and ubiquitin (Abcam, ab7254). Anti γ-tubulin antibody (Sigma, T6557) was used as a loading control. Antibodies were diluted at 1:1000 to 1:2000 at use. After three washes with TBST, secondary antibody (CWS) application was performed at RT for 1 hr using 5% milk in TBST followed by three additional washes with TBST. Bands were visualized using Immobilon Western ECL system and analyzed with Gel Pro Analysis software. For surface KCC2 detection, biotinylation of cell surface proteins was performed as described previously (Lee et al., 2010). Briefly, HEK293 cells transfected with KCC2 constructs or cultured neurons were washed two times with PBS containing 0.5 mM MgCl₂ and 1 mM CaCl₂ (PBS-CM) and then incubated with 2 ml of PBS-CM containing 1 mg/ml Sulfo-NHS-SS-Biotin (Pierce) for 30 min at 4°C. After labeling, the biotin reaction was quenched by washing three times with ice-cold PBS-CM containing 50 mM glycine and 0.1% BSA. Cells were then lysed with 1 ml lysis buffer and the lysate was collected. Protein concentration was determined using Micro BCA protein assay kit (Thermo Scientific). After correction for protein concentration, 40 μl of 1:1 slurry of UltraLink NeutrAvidin (Pierce) was added to the lysates to pull down the biotin-labeled surface proteins for 2 hr at 4°C. The NeutrAvidin beads were washed and bound materials were analyzed by SDS-PAGE.

Molecular cloning
To obtain a KCC2 plasmid in which the tyrosine phosphorylating sites, Y903A and Y1087A, were mutated (mKCC2), the KCC2 open reading frame (ORF) was amplified from the pCAGIG vector, incorporate Y903A and Y1087A mutation using the stratagene QuickChange method as described (Lee et al., 2010). For mutation of Y903 the following primers were used: (sense) TCCGGATCCAC TCGAGATGCTCAAC; (antisense) AATGTCTTCTCGAAGGTG TATGCTG. For mutation of Y1087 the following primers were used: (sense) TACACCTTCGAGAAGACATTGG; (antisense): ATTTACGTAG CGGCCGCTCAGGAGT ATGGATATCTGCAGAATTCCATGAAGTTTTCATCTCC.

Transfection
Commercially-available HEK293 cells, original transformed as reported (Graham et al., 1977), were co-transfected with KCC2 and GABA_A Rα1 or β2; KCC2 and APP/ or different APP fragments. Whenever necessary, KCC2 was replaced by mKCC2. Transfected HEK293 cells were washed with ice-cold PBS, centrifuged at 5000 rpm for 10 min at 4°C, and the precipitate was collected and homogenized using SDS lysis buffer, centrifuged at 14,000 rpm for 10 min at 4°C and supernatant and denatured for 20 min at 75°C. Supernatants were analyzed by western blotting.

Co-immunoprecipitation (Co-IP)
HEK293 cells were grown in DMEM (high glucose with L-glutamine) containing 10% FBS. For immunoprecipitation, HEK293 cells were plated onto 10 cm culture dishes, and grown to 70% confluency. Cell transfections were performed with lipofectamine 2000 (Invitrogen), following the manufacturer’s recommended protocol. 24–48 hr after transfection, cells were washed once with cold PBS then homogenized with 1 ml cold lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP40, and protease inhibitor) in 2 ml tubes. To remove cell debris, lysates were centrifuged for 20 min at 14,000 rpm at 4°C. Supernatants were incubated with 2 μl of KCC2 (Millipore, 07–432), APPc (Wang et al., 2007), or GABA_A R α1 (Millipore, 06–868), antibodies at 4°C overnight. Protein A agarose beads at 30 μl (Millipore) was added to each sample and they were incubated at 4°C for 2–3 hr. To control for nonspecific binding, protein lysates incubated with rabbit or mouse IgG and beads were processed in parallel. Subsequently, beads were washed three times with 500 μl of cold lysis buffer. Immunoprecipitates were eluted from the beads by adding 30 μl of SDS-PAGE sample buffer and heating for 20 min at 75°C. The eluates (15 μl) were analyzed by western blotting. For hippocampal lysates immunoprecipitation, we followed the HEK293 cells protocol above. Coomassie blue staining was conducted as described (Savas et al., 2015).

Proximity ligation assay (PLA)
HEK293 cells were grown in DMEM containing 10% FBS. For PLA (Söderberg et al., 2006), HEK293 cells were plated onto 10 cm culture dishes, and grown to 70% confluency. On the day of experiment, the wells were washed with 1xPBS and then added with 4% PFA and incubated for 10 min at RT without agitation. Then the cells were washed with PBS for 3 times, 5 min each, with agitation.
and treated with 0.5% Triton X-100 in PBS (PBST) for 10 min without agitation. Wash the cells with TBST for 3 times, 5 min each, with agitation. Block with Duolink II Blocking Solution (1x) for 1 hr at 37°C and then incubate with specific primary antibodies against KCC2 (Neuromab, 75–013) or APP (Abcam, ab15272). After wash with 1x Duolink II Wash Buffer A, cells were incubated with two PLA probes (Duolink II anti-Mouse MINUS and Duolink II anti-Rabbit PLUS) 1:5 in Antibody Diluent. Wash the slides in 1x Wash Buffer A for 2 times, 5 min each, with agitation at RT. Incubate the slides with Ligation-Ligase solution for 30 min at 37°C. Wash the slides in 1x Wash Buffer A with for 2 times, 2 min each. Then incubate the slides with Amplification-Polymerase solution for 100 min at 37°C. Wash the slides for 2 times, 10 min each, in 1x Duolink II Wash Buffer B and incubate with DAPI for 15 min at 37°C. Data was analyzed with a fluorescence microscope.

### KCC2 restoration experiment

KCC2 enhancers, CLP257 and CLP290 (Gagnon et al., 2013) were gifts from Yves De Koninck (Institut universitaire en santé mentale de Québec, QC, Canada).

CLP257 incubation: CLP257 was dissolved in 200 μl DMSO as 100 mM stock solution and diluted using aCSF to 100 μM. For slice recording, hippocampal slices (350 μm thick) of App−/− mice were cut using a vibratome (LeicaVT1000S) as described above for whole-cell recording in acute hippocampal slices. Slices were incubated for 2 hr in aCSF containing 100 μM CLP257 or DMSO and babbledd with 95% O₂ and 5% CO₂. For surface and total KCC2 protein levels evaluation, HEK293 cells, which was transfected with KCC2 were incubated for 2 hr in 100 μM CLP257 or DMSO.

CLP290 intraperitoneal injection: CLP290 was dissolved in HPCD and intraperitoneally administered once daily at a dose of 100 mg/kg for one week. HPCD injection group was used as vehicle control.

### Statistical analysis

Unless otherwise stated, data are displayed as mean±SEM. Student’s t-test was used for statistical analysis in two-group comparison. For comparison among multiple groups, one-way ANOVA or two-way ANOVA with post hoc tests were used. Statistical significance was set at p<0.05.

### Acknowledgements

The authors thank Dr. Yasunori Hayashi for suggestions on the manuscript; Zhijie Zhang for technical support. This work was supported by grants from the National Natural Science Foundation of China (31171018, 31171355), the Science and Technology Division of Guangdong (2013KJCX0054, 201607010320), and the Natural Science Foundation of Guangdong Province (2014A030313418, 2014 A030313440).
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**Author contributions**

MC, JW, JJ, XZ, KW, YL, QH, JZ, HL, NL, YW, Acquisition of data, Analysis and interpretation of data; NJJ, Acquisition of data, Drafting or revising the article; XR, Worked on HEK293 cell culture and transfection; HZ, CL, Analysis and interpretation of data, Contributed unpublished essential data or reagents; LY, Conception and design, Drafting or revising the article.

**Author ORCIDs**

Li Yang, [http://orcid.org/0000-0001-7448-8588](http://orcid.org/0000-0001-7448-8588)

**Ethics**

Animal experimentation: This study was conducted along the guidelines described in "The Guide for the Care and Use of Laboratory Animals" (Eighth Edition). All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#0312-11) of the South China Normal University. Every effort was made to minimize suffering.

**References**

Ben-Ari Y. 2002. Excitatory actions of gaba during development: the nature of the nurture. *Nature Reviews Neuroscience* 3:728–739. doi: 10.1038/nrn920, PMID: 12209121

Ben-Ari Y, Khalilov I, Kahle KT, Cherubini E. 2012. The GABA excitation/inhibition shift in brain maturation and neurological disorders. *The Neuroscientist* 18:467–486. doi: 10.1177/1073858412438697, PMID: 22547529

Bi R, Broutrum G, Foy MR, Thompson RF, Baudry M. 2000. The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. *PNAS* 97:3602–3607. doi: 10.1073/pnas.97.7.3602, PMID: 10725383

Blaesse P, Airaksinen MS, Rivera C, Kaila K. 2009. Cation-chloride cotransporters and neuronal function. *Neuron* 61:820–838. doi: 10.1016/j.neuron.2009.03.003, PMID: 19323993

Boulenguez P, Liabeuf S, Bos R, Bras H, Jean-Xavier C, Brocard C, Stil A, Darbon P, Cattaud E, Delipere E, Marsala M, Vinay L. 2010. Down-regulation of the potassium-chloride cotransporter KCC2 contributes to spasticity after spinal cord injury. *Nature Medicine* 16:302–307. doi: 10.1038/nm.2107, PMID: 20190766

Braat S, Kooi RF. 2015a. The GABAA receptor as a therapeutic target for neurodevelopmental disorders. *Neuron* 86:1119–1130. doi: 10.1016/j.neuron.2015.03.042, PMID: 26050032

Braat S, Kooi RF. 2015b. The GABAA receptor as a therapeutic target for neurodevelopmental disorders. *Neuron* 86:1119–1130. doi: 10.1016/j.neuron.2015.03.042, PMID: 26050032

Caraiscos VB, Elliott EM, You-Ten KE, Cheng YY, Belelli D, Newell JG, Jackson MF, Lambert JJ, Rosahl TW, Wafford KA, MacDonald JF, Orser BA. 2004. Tonic inhibition in mouse hippocampal cultures augments expression of functional GABA synapses. *The Journal of Physiology* 566:671–679. doi: 10.1113/jphysiol.2003.089821, PMID: 15961425

Chavas J, Marti A. 2003. Coexistence of excitatory and inhibitory GABA synapses in the cerebellar interneuron network. *Journal of Neuroscience* 23:2019–2031. PMID: 12657660

Chudotvorojeva I, Ivanov A, Rama S, Hübner CA, Pellegrino C, Ben-Ari Y, Medina I. 2005. Early expression of KCC2 in rat hippocampal cultures augments expression of functional GABA synapses. *The Journal of Physiology* 566:671–679. doi: 10.1113/jphysiol.2005.089821, PMID: 15961425

Coul UJA, Boudrears D, Bachand K, Prescott SA, Nault F, Sik A, De Koninck P, De Koninck Y. 2003. Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. *Nature* 424:938–942. doi: 10.1038/nature01868, PMID: 12931188

Curia G, Papounin T, Séguela P, Avoli M. 2009. Downregulation of tonic GABAAergic inhibition in a mouse model of fragile X syndrome. *Cerebral Cortex* 19:1515–1520. doi: 10.1093/cercor/bhn159, PMID: 18787232

De Strooper B, Annaert W. 2000. Proteolytic processing and cell biological functions of the amyloid precursor protein. *Journal of Cell Science* 113:1857–1870. PMID: 10806097

Ferando I, Faas GC, Mody I. 2016. Diminished KCC2 confounds synapse specificity of LTP during senescence. *Nature Neuroscience* 19:1197–1200. doi: 10.1038/nn.4357, PMID: 27500406

Fiszman ML, Barberis A, Lu C, Fu Z, Erdélyi F, Szabó G, Vicini S. 2005. NMDA receptors increase the size of GABAAergic terminals and enhance GABA release. *Journal of Neuroscience* 25:2024–2031. doi: 10.1523/JNEUROSCI.4980-04.2005, PMID: 15723842

Gagnon M, Bergeron MJ, Lavertu G, Castonguay A, Tripathy S, Bonin RP, Perez-Sanchez J, Boudreurs D, Wang B, Dumas L, Valade I, Bachand K, Jacob-Wagner M, Tardif C, Kianicka I, Isenring P, Attardo G, Coul JA, De Koninck Y. 2013. Chloride extrusion enhancers as novel therapeutics for neurological disorders. *Nature Medicine* 19:1524–1528. doi: 10.1038/nm.3356, PMID: 24097188
Gauvain G, Chamma I, Chevy Q, Cabezas C, Irinopoulou T, Bodrug N, Carnaud M, Lévi S, Ponceur JC. 2011. The neuronal K-Cl cotransporter KCC2 influences postsynaptic AMPA receptor content and lateral diffusion in dendritic spines. *PNAS* **108**:15474–15479. doi: 10.1073/pnas.1107893108, PMID: 21878564

Goswami SP, Bucurenciu I, Jonas P. 2012. Miniature IPSCs in hippocampal granule cells are triggered by voltage-gated Ca2+ channels via microdomain coupling. *Journal of Neuroscience* **32**:14294–14304. doi: 10.1523/JNEUROSCI.0104-11.2012, PMID: 23055500

Graham FL, Smiley J, Russell WC, Nain R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *Journal of General Virology* **36**:59–74. doi: 10.1099/0022-1317-36-1-59, PMID: 886304

Han S, Tai C, Jones CJ, Scheuer T, Catterall WA. 2014. Enhancement of inhibitory neurotransmission by GABAA receptors having α2,3-subunits ameliorates behavioral deficits in a mouse model of autism. *Neuron* **81**:1282–1289. doi: 10.1016/j.neuron.2014.01.016, PMID: 24656250

Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. *Science* **297**:353–356. doi: 10.1126/science.1072994, PMID: 12130773

Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. 2006. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. *Neuron* **52**:831–843. doi: 10.1016/j.neuron.2006.10.035, PMID: 17145504

Jo S, Yanishkin O, Hwang YJ, Chun YE, Park M, Woo DH, Bae JY, Kim T, Lee J, Chun H, Park HJ, Lee DY, Hong J, Kim HY, Oh SJ, Park SJ, Lee H, Yoon BE, Kim Y, Jeong Y, et al. 2014. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. *Nature Medicine* **20**:886–896. doi: 10.1038/nm.3639, PMID: 24973918

Kaila K, Price TJ, Payne JA, Puskarjov M, Voipio J. 2014. Cation-chloride cotransporters in neuronal development, plasticity and disease. *Nature Reviews Neuroscience* **15**:637–654. doi: 10.1038/nn3819, PMID: 25234263

Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. 2003. APP processing and synaptic function. *Neuron* **37**:925–937. doi: 10.1016/S0896-6273(03)00124-7, PMID: 12670422

Kim SH, Tang YP, Sisodia SS. 2006. Abeta star: a light onto synaptic dysfunction? *Nature Medicine* **12**:760–761. doi: 10.1038/nm0706-760, PMID: 16829934

Klevanski M, Herrmann U, Weyer SW, Fol R, Cartier N, Wolfer DP, Caldwell JH, Korte M, Müller UC. 2015. The APP intracellular domain is required for normal synaptic morphology, Synaptic Plasticity, and Hippocampus-Dependent Behavior. *Journal of Neuroscience* **35**:16018–16033. doi: 10.1523/JNEUROSCI.2009-15.2015, PMID: 26658856

Lee HH, Walker JA, Williams JR, Goodier RJ, Payne JA, Moss SJ. 2007. Direct protein kinase C-dependent phosphorylation regulates the cell surface stability and activity of the potassium chloride cotransporter KCC2. *Journal of Biological Chemistry* **282**:29777–29784. doi: 10.1074/jbc.M705053200, PMID: 17693402

Lee HH, Jurd R, Moss SJ. 2010. Tyrosine phosphorylation regulates the membrane trafficking of the potassium chloride co-transporter KCC2. *Molecular and Cellular Neuroscience* **45**:173–179. doi: 10.1016/j.mcn.2010.06.008, PMID: 20609929

Lee HH, Deeb TZ, Walker JA, Davies PA, Moss SJ. 2011. NMDA receptor activity downregulates KCC2 resulting in depolarizing GABAA receptor-mediated currents. *Nature Neuroscience* **14**:736–743. doi: 10.1038/nn.2806, PMID: 21532577

Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE, Südhof TC, Zheng H. 2010. Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. *PNAS* **107**:17362–17367. doi: 10.1073/pnas.1012568107, PMID: 20855613

Palop JJ, Mucke L. 2010. Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. *Nature Neuroscience* **13**:812–818. doi: 10.1038/nn.2583, PMID: 20581818

Plotkin MD, Snyder EY, Hebert SC, Delpire E. 1997. Expression of the Na-K-2Cl cotransporter is developmentally regulated in postnatal rat brains: a possible mechanism underlying GABA’s excitatory role in immature brain development. *Journal of Neurobiology* **33**:781–795. doi: 10.1002/(SICI)1097-4695(19971120)33:6<781::AID-NERU6>3.0.CO;2-5, PMID: 9369151

Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. 2006. Synapse formation and function is modulated by the amyloid precursor protein. *Journal of Neuroscience* **26**:7212–7221. doi: 10.1523/JNEUROSCI.1450-06.2006, PMID: 16822978

Rivera C, Voipio J, Payne JA, Rusuuvuori E, Lahtinen H, Lamsa K, Pirvola U, Saarma M, Kaila K. 1999. The K+-Cl-co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. *Nature* **397**:251–255. doi: 10.1038/16697, PMID: 9930699

Saliba RS, Pangalos M, Moss SJ. 2008. The ubiquitin-like protein Plic-1 enhances the membrane insertion of GABAA receptors by increasing their stability within the endoplasmic reticulum. *Journal of Biological Chemistry* **283**:18538–18544. doi: 10.1074/jbc.M802077200, PMID: 18467327

Savas JW, Ribiero LF, Wiera KD, Wright R, DeNardo-Wilke LA, Rice HC, Chamma I, Wang YZ, Zemla R, Lavalée-Adam M, Vennekens KM, O’Sullivan ML, Antonios JK, Hall EA, Thomeine O, Attie AD, Yates JR, Ghosh A, de Wit J. 2015. The sorting receptor SorCS1 regulates trafficking of neuroin and AMPA receptors. *Neuron* **87**:764–780. doi: 10.1016/j.neuron.2015.08.007, PMID: 26291160

Schubert W, Prior R, Weidemann A, Dirksen H, Multhaup G, Masters CL, Beyreuther K. 1991. Localization of alzheimer beta A4 amyloid precursor protein at central and peripheral synaptic sites. *Brain Research* **563**:184–194. doi: 10.1016/0006-8993(91)91532-4, PMID: 1786532
Seabrook GR, Smith DW, Bowery BJ, Easter A, Reynolds T, Fitzjohn SM, Morton RA, Zheng H, Dawson GR, Sirinathsinghji DJ, Davies CH, Collingridge GL, Hill RG. 1999. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropearmacology 38: 349–359. doi: 10.1016/S0028-3908(98)00204-4, PMID: 10219973

Selkoe DJ. 2002. Alzheimer’s disease is a synaptic failure. Science 298: 789–791. doi: 10.1126/science.1074069, PMID: 12399581

Succol F, Fiumelli H, Benfenati F, Cancetda L, Barberis A. 2012. Intracellular chloride concentration influences the GABA receptor subtype composition. Nature Communications 3: 738. doi: 10.1038/ncomms1744, PMID: 22415829

Söderberg O, Gullberg M, Jarvius M, Ridderstråle K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U. 2006. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nature Methods 3: 995–1000. doi: 10.1038/nmeth947, PMID: 17072308

Tamamaki N, Yang L, Miyazaki J, Obata K, Kaneko T. 2003. Green fluorescent protein expression and colocalization with calretinin, parvalbumin, and somatostatin in the GAD67-GFP knock-in mouse. The Journal of Comparative Neurology 467: 60–79. doi: 10.1002/cne.10905, PMID: 14574680

Tang X, Kim J, Zhou L, Wengert E, Zhang L, Wu Z, Caramou C, Muetri AR, Marchetto MC, Gage FH, Chen G. 2016. KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome. Nature 113: 751–756. doi: 10.1037/0021-9967.113.6.751, PMID: 26733678

Tao R, Li C, Newburn EN, Ye T, Lipska BK, Herman MM, Weinberger DR, Kleinman JE, Hyde TM. 2012. Transcript-specific associations of SLC12A5 (KCC2) in human prefrontal cortex with development, schizophrenia, and affective disorders. Journal of Neuroscience 32: 5216–5222. doi: 10.1523/JNEUROSCI.4626-11.2012, PMID: 22496567

Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, Mucke L, Palop JJ. 2012. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in alzheimer model. Cell 149: 708–721. doi: 10.1016/j.cell.2012.02.046, PMID: 22541439

Wake H, Watanabe M, Moorhouse AJ, Kanematsu T, Horibe S, Matsukawa N, Asai K, Ojika K, Hirata M, Nabekura J. 2007. Early changes in KCC2 phosphorylation in response to neuronal stress result in functional downregulation. Journal of Neuroscience 27: 1642–1650. doi: 10.1525/JNEUROSCI.3104-06.2007, PMID: 17301172

Wang B, Yang L, Wang Z, Zheng H. 2007. Amyloid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter. PNAS 104: 14140–14145. doi: 10.1073/pnas.0704070104, PMID: 17709753

Wang Z, Wang B, Wang Y, Guo Q, Aithmitti N, Songyang Z, Zheng H. 2009. Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. Journal of Neuroscience 29: 10788–10801. doi: 10.1523/JNEUROSCI.2132-09.2009, PMID: 19726636

Wang B, Wang Z, Sun L, Yang L, Li H, Cole AL, Rodriguez-Rivera J, Lu H-C, Zheng H. 2014a. The amyloid precursor protein controls adult hippocampal neurogenesis through GABAergic interneurons. Journal of Neuroscience 34: 13314–13325. doi: 10.1523/JNEUROSCI.2848-14.2014

Wang B, Wang Z, Sun L, Yang L, Li H, Cole AL, Rodriguez-Rivera J, Lu HC, Zheng H. 2014b. The amyloid precursor protein controls adult hippocampal neurogenesis through GABAergic interneurons. Journal of Neuroscience 34: 13314–13325. doi: 10.1523/JNEUROSCI.2848-14.2014, PMID: 25274811

Wei W, Nguyen LN, Kessels HW, Hagivara H, Sosida S, Malinow R. 2010. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nature Neuroscience 13: 190–196. doi: 10.1038/nn.2476, PMID: 20037574

Wu Z, Guo Z, Gearing M, Chen G. 2014. Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an alzheimer’s [corrected] disease model. Nature Communications 5: 4159. doi: 10.1038/ncomms5159, PMID: 24923909

Yang L, Wang B, Long C, Wu G, Zheng H. 2007. Increased asynchronous release and aberrant calcium channel activation in amyloid precursor protein deficient neuromuscular synapses. Neuroscience 149: 768–778. doi: 10.1016/j.neuroscience.2007.08.025, PMID: 17919826

Yang L, Wang Z, Wang B, Justice NJ, Zheng H. 2009. Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity. Journal of Neuroscience 29: 15660–15668. doi: 10.1523/JNEUROSCI.4104-09.2009, PMID: 20016080

Yarishkin O, Lee J, Jo S, Hwang EM, Lee CJ. 2015. Disinhibitory action of astrocytic GABA at the perforant path to dentate gyrus granule neuron synapse reverses to inhibitory in Alzheimer’s Disease Model. Experimental Neurobiology 24: 211–218. doi: 10.5607/en.2015.24.3.211, PMID: 26412970

Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisoda SS, Chen HY, Van der Ploeg LH. 1995. beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81: 525–531. doi: 10.1016/0092-8674(95)90073-X, PMID: 7758106

Zucker RS, Reggehr WR. 2002. Short-term synaptic plasticity. Annual Review of Physiology 64: 355–405. doi: 10.1146/annurev.physiol.64.092501.114547, PMID: 11826273